CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced that more than 49 oral and poster presentations featuring VELCADE and the Company’s pipeline molecules will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Orlando, Florida, May 29 – June 2, 2009. These data include two oral presentations on studies examining the use of VELCADE based combinations in patients with previously untreated multiple myeloma (MM), and one poster on the use of a VELCADE based combination in patients with relapsed or refractory follicular lymphoma. Clinical and preclinical data also will be presented on three Millennium oncology pipeline products, including MLN8237, an oral compound designed to selectively inhibit Aurora A kinase, discovered and developed by Millennium scientists; and MLN4924, a small molecule aimed at inhibiting the NEDD8-Activating Enzyme (NAE), a Millennium discovered target.
